Mylan Hits Back At ‘Misleading’ FDA Warning Letter
Claims Agency Warning Letter Contains ‘Misleading Information’ On Nitrosamines
Mylan has hit back at “misleading information” circulating in connection with a recent FDA warning letter – including some statements within the letter itself – as it highlighted its proactive efforts in investigating “all potential risks associated with inquiries related to nitrosamine impurities.”
You may also be interested in...
Agency guidance establishes process for ridding unsafe levels of the probable carcinogens from the pharmaceutical supply chain.
Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.